Related Experiment Videos
Aspirin-like molecules that inhibit human immunodeficiency virus 1 replication
Cândida F Pereira1, Judith T M L Paridaen, Karla Rutten
1Eijkman-Winkler Center, HpG04.614, University Medical Center Utrecht, Heidelberglaan 100, NL-3584, CX Utrecht, The Netherlands. c.f.pereira@lab.azu.nl
Antiviral Research
|May 28, 2003
Summary
o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS), an anti-inflammatory drug, inhibits human immunodeficiency virus type 1 (HIV-1) replication. This study reveals APHS targets the reverse transcription process during early HIV-1 infection stages.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Some anti-inflammatory compounds exhibit anti-human immunodeficiency virus (HIV) activity.
- o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS) is a novel non-steroidal anti-inflammatory molecule with potential antiviral properties.
Purpose of the Study:
- To elucidate the mechanism of action of APHS against HIV-1 replication.
- To evaluate the efficacy and specificity of APHS in inhibiting HIV-1 at different infection stages.
Main Methods:
- APHS efficacy was tested against various HIV-1 strains in primary immune cells (PBMC, macrophages, lymphocytes).
- Inhibition of viral replication, entry, and reverse transcription was assessed.
- Dose-dependent effects and toxicity of APHS were determined.
Main Results:
- APHS demonstrated dose-dependent inhibition of HIV-1 replication in primary cells with IC50 values around 10 microM.
- APHS showed minimal toxicity, with 50% toxic concentrations ranging from 100-200 microM.
- APHS did not inhibit viral entry or replication post-proviral integration but effectively blocked gag DNA synthesis during reverse transcription.
Conclusions:
- APHS is a potent inhibitor of early HIV-1 replication, specifically targeting the reverse transcription step.
- APHS represents a promising therapeutic candidate for HIV-1 treatment, acting on a critical stage of the viral life cycle.